drugset / Trial / NCT02152332

A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

NCT02152332

Phase 1 Completed 64 enrolled Janssen Research & Development, LLC
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effects of JNJ-54861911 on the QT/QTc intervals in healthy participants, when administered at therapeutic (50 milligram \[mg\] once-daily) and supratherapeutic (150 mg once-daily) doses for 7 days.

Timeline

Start
2014-07
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Atabecestat Small molecule 50 mg
Subject Atabecestat Small molecule 150 mg
Subject Moxifloxacin Small molecule 400 mg

Indications

No indication recorded.